[5] BlairHA. Dimethyl Fumarate:A Review inRelapsing-Remitting MS. Drugs. 2019 Dec;79(18):1965-1976.[6] Biogenpress release. New data at AAN showcase Biogen ’ s commitment to advancinginnovationin MS. Available at:https://investors.biogen.com/news-releases/news-release-details/new-data-aan-showcase-biogens-commitmentadvancing-innovation-ms. Lastaccessed July 2020.
[7] KadowakiA, Quintana FJ. The gut–cns axis in multiple sclerosis. Trendsin Neurosciences. 2020;43(8):622-634.
[8] DeAngelis F, John NA, Brownlee WJ. Disease-modifying therapies for multiplesclerosis. BMJ. Published online November 27, 2018:k4674.
[9] AllingtonD. New approaches in the management of multiple sclerosis. DDDT. Publishedonline November 2010:343-66.
[10] FilippiM, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.
[11] 李雄. 治疗多发性硬化的新药:富马酸二甲酯[J]. 中国医院用药评价与分析, 2015(05):696-699.
[12] MillsEA,Ogrodnik MA, PlaveA, et al. EmergingUnderstanding of the Mechanism of Action for Dimethyl Fumarate in the Treatmentof Multiple Sclerosis. Front Neurol. 2018 Jan 23;9:5.
[13] VigliettaV, Miller D, Bar-Or A, et al. Efficacy of delayed-releasedimethyl fumarate in relapsing-remitting multiple sclerosis:integrated analysis of the phase 3 trials[J]. Ann Clin Transl Neurol, 2015, 2(2):103-118.
[14] Gold Ret al. Safety and Efficacy in Patients Treated With Dimethyl Fumarate andFollowed For 13 Years:Final Results of ENDORSE. 8th Joint ACTRIMS-ECTRIMS Meeting, 2020.
[15] Saida T, Yamamura T, Kondo T, et al. A randomized placebo-controlled trial of delayed-releasedimethyl fumarate in patients with relapsing-remitting multiple sclerosis fromEast Asia and other countries[J]. BMC Neurol, 2019, 19(1):5.
[16] NationalHealth Service. Treatment Algorithm for Multiple Sclerosis Disease-ModifyingTherapies. Updated 2019.
[17] Cada DJ, Levien TL, BakerDE. Dimethyl Fumarate[J]. Hosp Pharm. 2013 Sep;48(8):668-79.
[18] 《中国多发性硬化患者健康洞察蓝皮书暨2021版中国多发性硬化患者生存质量报告》要点解读. http://www.mdweekly.com.cn/html/xinwen/xingyedongtai/2021/0227/32847.html
[19] 《2020中国多发性硬化患者综合社会调查报告》发布. https://www.jksb.com.cn/html/news/academic/2020/1223/168321.html
[20] 刘翕然,张星虎. 多发性硬化的疾病修正治疗研究进展[J].中国神经免疫学和神经病学杂志, 2018, 025(004):284-292.
[21] MontalbanX, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatmentof people with multiple sclerosis. Mult Scler. 2018;24(2):96-120.
[22] Rae-GrantA, Day GS, Marrie RA, et al. Practice guideline recommendations summary:disease-modifying therapies for adults with multiplesclerosis:report of theguideline development, dissemination, and implementation subcommittee of the american academy ofneurology. Neurology. 2018;90(17):777-788.
[23] 中国免疫学会神经免疫分会,中华医学会神经病学分会神经免疫学组.多发性硬化诊断和治疗中国专家共识(2018版)[J].中国神经免疫学和神经病学杂志,2018,25(6):387-394.
[24] Medications_ National Multiple Sclerosis Society. https://www.nationalmssociety.org/Treating-MS/Medications
[25] 多发性硬化症的治疗. http://hkmss.org/wordpress/index.php/public-resources/treatment-for-ms-chi/
[26] 速递| 中国首部罕见病多发性硬化患者生存报告在京发布. https://mp.weixin.qq.com/s/zA5rArsMnYCJU5AAly_BSg.